Insulin Resistance  >>  Pegasys (pegylated interferon α -2a)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pegasys (pegylated interferon α -2a) / Roche
NCT00274495: Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver

Terminated
4
30
US
Rosiglitazone and Pegasys/Ribavirin
Beth Israel Medical Center
Chronic Hepatitis C Infection, Fatty Liver
 
10/07
NCT00545233: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.

Completed
4
155
US
peginterferon alfa-2a [Pegasys], Pegasys, ribavirin [Copegus], Copegus, Pioglitazone, Actos
Hoffmann-La Roche
Hepatitis C, Chronic
12/10
12/10

Download Options